STA
KYNB

Summit Trail Advisors’s Kyntra Bio KYNB Stock Holding History

Summit Trail Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-39
Closed -$60K – 346
2018
Q2 		$60K Buy
+39
New +$50.8K 0.02% 286
2018
Q1 		– Sell
-46
Closed -$58K – 852
2017
Q4 		$58K Buy
+46
New +$57.7K 0.01% 777

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Summit Trail Advisors's KYNB Position: Q3 2018 in Review

Summit Trail Advisors sold out of Kyntra Bio (KYNB) in Q3 2018, closing a stake of 39 shares — an estimated $60K sold.

Summit Trail Advisors first reported a position in KYNB in Q4 2017 and held it in 2 quarters. The position peaked at $60K in Q2 2018. 187 funds tracked by Wall St. Rank hold KYNB as of Q3 2018.

  • Summit Trail Advisors reported no remaining Kyntra Bio position as of Q3 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 39 Kyntra Bio shares in Q3 2018, an estimated $60K.
  • Summit Trail Advisors first reported a position in Kyntra Bio in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's Kyntra Bio position peaked at $60K in Q2 2018.
  • 187 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2018.

Based on Summit Trail Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.